Volitionrx Ltd (VNRX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Volitionrx Ltd stock (VNRX) is currently trading at $0.19. Volitionrx Ltd PS ratio (Price-to-Sales) is 18.52. Analyst consensus price target for VNRX is $2.06. WallStSmart rates VNRX as Sell.
- VNRX PE ratio analysis and historical PE chart
- VNRX PS ratio (Price-to-Sales) history and trend
- VNRX intrinsic value — DCF, Graham Number, EPV models
- VNRX stock price prediction 2025 2026 2027 2028 2029 2030
- VNRX fair value vs current price
- VNRX insider transactions and insider buying
- Is VNRX undervalued or overvalued?
- Volitionrx Ltd financial analysis — revenue, earnings, cash flow
- VNRX Piotroski F-Score and Altman Z-Score
- VNRX analyst price target and Smart Rating
Volitionrx
📊 No data available
Try selecting a different time range
Smart Analysis
Volitionrx Ltd (VNRX) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Volitionrx Ltd (VNRX) Key Strengths (1)
Revenue surging 32.20% year-over-year
Supporting Valuation Data
Volitionrx Ltd (VNRX) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Very expensive at 18.5x annual revenue
Very expensive at 38.4x book value
Micro-cap company with very limited liquidity and high volatility
Low institutional interest, mostly retail-driven
Supporting Valuation Data
Volitionrx Ltd (VNRX) Detailed Analysis Report
Overall Assessment
This company scores 20/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 1 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth. Growth metrics are encouraging with Revenue Growth at 32.20%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (18.52), Price/Book (38.44) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -730.00%, Operating Margin at -813.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -730.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 32.20% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
VNRX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
VNRX's Price-to-Sales ratio of 18.52x trades at a deep discount to its historical average of 2366.07x (5th percentile). The current valuation is 100% below its historical high of 8927.84x set in Dec 2014, and 8% above its historical low of 17.16x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~60.4x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Volitionrx Ltd (VNRX) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Volitionrx Ltd is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 1M with 32% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue growing at 32% YoY, reaching 1M. This pace significantly outperforms most MEDICAL DEVICES peers.
Spending 155% of revenue (2M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -3M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Volitionrx Ltd maintain 32%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Volitionrx Ltd.
Bottom Line
Volitionrx Ltd is a high-conviction growth story with revenue accelerating at 32% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Volitionrx Ltd(VNRX)
NYSE MKT
HEALTHCARE
MEDICAL DEVICES
USA
VolitionRx Limited, a multinational epigenetics company, is dedicated to developing blood tests to help diagnose a variety of cancers and other diseases globally. The company is headquartered in Austin, Texas.